Deep sequencing of plasma and proviral HIV-1 to establish coreceptor usage: What is the clinical impact of the quasispecies distribution?

Journal of Infectious Diseases

Volumn 204, Issue 6, 2011, Pages 971-973

  Abbate, Isabella ^a   Rozera, Gabriella ^a   Giombini, Emanuela ^a   D'Offizi, Gianpiero ^a   Nicastri, Emanuele ^a   Narciso, Pasquale ^a   Ippolito, Giuseppe ^a   Capobianchi, Maria R ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; VIRUS DNA;

CONSENSUS SEQUENCE; GENETIC ALGORITHM; GENOTYPE; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; PYROSEQUENCING; QUASISPECIES DISTRIBUTION; SEQUENCE ANALYSIS; SPECIES DISTRIBUTION; ULTRADEEP PYROSEQUENCING; VIRUS GENOME; VIRUS LOAD;

ANTI-HIV AGENTS; CYCLOHEXANES; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, HIV; TRIAZOLES; VIRAL TROPISM; VIROLOGY;

EID: 80052229865     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir427     Document Type: Letter

References (11)

1. Swenson L.C., Mo T., Dong W.W., et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011; 203:237-45.
2. Kuritzkes D.R. Genotypic tests for determining coreceptor usage of HIV-1. J Infect Dis 2011; 203:146-8.
3. Abbate I., Rozera G., Tommasi C., et al. Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients candidate to CCR5 antagonist treatment. Clin Microbiol Infect 2011; 17:725-31.
4. Lin N.H., Kuritzkes D.R. Tropism testing in the clinical management of HIV-1 infection. Curr Opin HIV AIDS 2009; 4:481-7.
5. Sánchez V., Masiá M., Robledano C., Padilla S., Ramos J.M., Gutiérrez F. Performance of genotypic algorithms for predicting HIV-1 tropism measured against the enhanced-sensitivity Trofile coreceptor tropism assay. J Clin Microbiol 2010; 48:4135-9.
6. Svicher V., D'Arrigo R., Alteri C., et al. Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR study group. New Microbiol 2010; 33:95-206.
7. Rozera G., Abbate I., Bruselles A., et al. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology 2009; 12:6-15.
8. Prosperi M.C., Bracciale L., Fabbiani M., et al. Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology 2010; 7:56 doi:10.1186/1742-4690-7-56.
9. Raymond S., Delobel P., Mavigner M., et al. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS 2010; 24:2305-12.
10. Seclén E., Del Mar González M., De Mendoza C., Soriano V., Poveda E. Dynamics of HIV tropism under suppressive antiretroviral therapy: Implications for tropism testing in subjects with undetectable viraemia. J Antimicrob Chemother 2010; 65:1493-6.
11. Soulié C., Fourati S., Lambert-Niclot S., et al. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. J Antimicrob Chemother 2010; 65:749-51.